NICE Does Not Recommend Cetuximab Plus Platinum-Based Chemotherapy for Head and Neck Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




NICE Does Not Recommend Cetuximab Plus Platinum-Based Chemotherapy for Head and Neck Cancer

LONDON -- June 25, 2009 -- The National Institute for Health and Clinical Excellence (NICE) has published guidance on the use of cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck.

The guidance does not recommend cetuximab in combination with platinum-based chemotherapy as a treatment option for patients with this type of head and neck cancer.

People currently receiving cetuximab in combination with platinum-based chemotherapy for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck should have the option to continue treatment until they and their clinician consider it appropriate to stop.

"When reaching today's decision the appraisal committee took account of all of the available evidence on the use of cetuximab, in combination with platinum-based chemotherapy, when compared with the existing treatment options already available to patients with metastatic squamous cell head and neck cancer," said Andrew Dillon, NICE, London, United Kingdom.

"The committee noted the existing uncertainty over the clinical effectiveness of the treatment and the costs of the treatment when compared to those currently available."

The Committee also took into account the supplementary advice provided by NICE to be taken into account when appraising treatments at the end of life. The Committee noted that cetuximab was used for a small population with a short life-expectancy for a devastating disorder but it did not offer sufficiently greater benefits to these patients compared to existing treatments."

The guidance is available at: http://www.nice.org.uk/TA172

SOURCE: National Institute for Health and Clinical Excellence

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities